The experimental inflammation drug was seen as having 'pipeline-in-a-product' potential, meaning it could be effective in treating a range of conditions. However, the recent clinical hold by the FDA could significantly impact the development and potential of zelnecirnon.
Nipun Davar's appointment, with his vast experience in small molecule product development and commercial manufacturing, is a major boost for RAPT's leadership team as they progress their drug candidates zelnecirnon and tivumecirnon in late-stage clinical trials for inflammatory diseases and oncology indications.
RAPT Therapeutics股票讨论区
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
Yesterday My support Halt up ♥️🌹✈️
My people rich? ♥️🌹✈️
buy or no buy? 🙊
GP morgan? ,🙈
Offering NEWS? 🙈
wat ta fut 😂😝
暂无评论